Is It Too Late To Consider Johnson & Johnson (JNJ) After A 46.9% One Year Rally?

• Wondering if Johnson & Johnson at around US$222 per share offers good value today, or if most of the opportunity has already played out.
• The stock is up 46.9% over the last year and 7.3% year to date, even after a 3.2% move over the past week and a 6.7% pullback over the past month.
• Recent headlines have focused on Johnson & Johnson’s position in global healthcare and its role in key product categories. This helps frame how investors are thinking about its future cash generation and resilience. At the same time, ongoing discussions around regulation and competition continue to influence how the market prices that outlook.
• Simply Wall St currently assigns Johnson & Johnson a valuation score of 3 out of 6. The next step is to look at how different valuation approaches judge the stock and then finish with a framework that can help you interpret those signals more clearly.

Johnson & Johnson delivered 46.9% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes the cash that a company is expected to generate in the future and discounts those amounts back to today, giving you an estimate of what the business might be worth right now.

For Johnson & Johnson, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest reported free cash flow is about $17.0b, and analyst-based plus extrapolated projections from Simply Wall St point to free cash flow of $35.9b by 2030. Between 2026 and 2035, the ten year projections range from about $26.5b to $44.8b a year, all expressed in today’s money using discounting.

When all those discounted cash flows are added together, the resulting estimated intrinsic value is US$374.05 per share. Compared with the current share price of about US$222, the DCF output suggests the stock trades at a 40.5% discount to this estimate, which points to a meaningful gap between price and modeled value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 40.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Johnson & Johnson.

Approach 2: Johnson & Johnson Price vs Earnings

For a profitable company like Johnson & Johnson, the P/E ratio is a useful yardstick because it ties the share price directly to the earnings that support it. In general, higher growth expectations or lower perceived risk can justify a higher “normal” P/E, while slower growth or higher risk usually align with a lower P/E.

Johnson & Johnson currently trades on a P/E of 25.46x. This sits well above the Pharmaceuticals industry average of 16.05x and is very close to the peer group average of 25.35x. That indicates the stock is priced broadly in line with similar companies but at a premium to the wider industry.

Simply Wall St’s Fair Ratio for Johnson & Johnson is 28.40x. This is its proprietary estimate of what the P/E might be, given the company’s earnings profile, profit margins, risks, industry and market cap. This goes a step further than a simple comparison with peers or the industry because it adjusts for those company-specific characteristics rather than assuming all businesses deserve the same multiple. Compared with the current P/E of 25.46x, the Fair Ratio indicates the stock is trading below that modelled level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach your own story about Johnson & Johnson to the numbers by linking a view of its business, forecast revenue, earnings and margins to a Fair Value. You can then compare that Fair Value to today’s price, while the platform keeps your view updated when new earnings or news arrive. This is why one Narrative on Johnson & Johnson might see it as a high quality compounder with fair value around US$246.46, while another, more cautious Narrative might set fair value closer to US$133. This gives you a clear sense of how different assumptions can lead to very different conclusions about whether the current price looks high, low or roughly in line with expectations.

For Johnson & Johnson, we will make it really easy for you with previews of two leading Johnson & Johnson Narratives:

🐂 Johnson & Johnson Bull Case

Fair value in this narrative: US$252.42 per share

Implied discount to this fair value vs last close: about 11.9%

Modeled revenue growth rate: 6.5%

• Analysts expect Johnson & Johnson to grow revenue and lift profit margins over the next few years, supported by next generation therapies in oncology and immunology.
• Large planned investment in manufacturing, R&D and MedTech, together with acquisitions like Intra Cellular Therapies, is used to justify higher future earnings in the model.
• This view sees the current share price as close to the analyst consensus fair value, and stresses that investors should test the assumptions on growth, margins and valuation multiples for themselves.

🐻 Johnson & Johnson Bear Case

Fair value in this narrative: US$173.55 per share

Implied premium to this fair value vs last close: about 28.2%

Modeled revenue growth rate: 6.3%

• This narrative focuses on patent expiries, litigation and drug approval risk, and concludes that these could justify a lower valuation than the current share price.
• It assumes solid revenue growth and healthy profit margins, but applies a lower future P/E multiple than today to reflect those risks and a more cautious stance on the pipeline.
• The author expects dividends and buybacks to remain affordable, yet sees the stock as priced above their estimate of fair value based on 2028 to 2029 earnings and discount rate assumptions.

Do you think there’s more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com